INVESTORS PRESENTATION
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals released its June 2025 investor presentation showcasing strong financial growth, with total income rising to Rs 456.3 Cr in FY25 from Rs 135.3 Cr in FY21. EBITDA grew to Rs 55.1 Cr at a 12.1% margin, while PAT reached Rs 20.8 Cr with a 4.6% margin. ROCE stood at a healthy 31.8%. The company is diversifying beyond generics into pet care (Freossi), nutraceuticals, cosmeceuticals, and mobility, with 697 registered products across 52 countries. Recent initiatives include India's first veterinary CBCT diagnostic centre, entry into large animal healthcare, and expansion of beauty and nutrition divisions. Revenue mix remains heavily domestic at 83%. Manufacturing capacity has scaled significantly across granulation, compression, capsules, topicals, and lotions since FY17.
The presentation highlights consistent revenue and margin expansion over five years and signals management confidence in future margin improvement driven by new-age and non-pharma products. For shareholders, this reflects a growth-oriented, diversifying pharma business, though profitability margins remain thin and current borrowings have risen sharply (from Rs 12.8 Cr to Rs 156.8 Cr in current liabilities), warranting attention to working capital and debt levels.